Background: The international guideline for urticaria recommends the use of the Urticaria Activity Score 7 (UAS7) and the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) to assess patients with chronic spontaneous urticaria (CSU) for their disease activity and impact on quality of life, respectively. Over the last decade, both tools have been validated in many different languages but not in Arabic.
Objective: To validate the Arabic UAS7 and CU-Q2oL in patients with CSU in Lebanon.
Methods: After a structured translation process of both instruments into Arabic, their construct and known-groups validity as well as internal consistency reliability were tested in a longitudinal prospective study using a cluster sample of 152 Lebanese CSU patients. The study also included a repetitive administration of both instruments in 2-week intervals in 44 patients in order to assess their test-retest reliability.
Results: Both the Arabic UAS7 and CU-Q2oL demonstrated high internal consistency (Cronbach alpha of 0.95 and 0.82, respectively) and moderate-to-high test-retest reliability (intraclass coefficient of 0.61 and 0.91, respectively). Exploratory factor analysis of the Arabic CU-Q2oL revealed five components that explained 81.8% of the total variance. Significant correlations were found between the Arabic CU-Q2oL and the Dermatology Life Quality Index (DLQI) (r = 0.86) and mild-to-moderate correlations between the Arabic UAS7 and CU-Q2oL (r = 0.52) as well as the DLQI (r = 0.51).
Conclusions: Our findings demonstrate that the Arabic versions of the UAS7 and the CU-Q2oL are valid and reliable patient-reported outcome measures in patients with CSU in Lebanon.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ijd.15006 | DOI Listing |
Adv Biomed Res
September 2024
Department of Traditional Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran.
Background: Chronic spontaneous urticaria (CSU) is a challenging disorder that severely impacts the quality of life. The current study objective was to evaluate the efficacy and safety of jujube oxymel (JO) for treating CSU.
Materials And Methods: In this randomized double-blind controlled trial, 92 patients (aged 12-65) with CSU were randomly allocated to JO or placebo groups.
Eur J Dermatol
August 2024
Riga Stradiņš University, Riga, Latvia, Pauls Stradiņš Clinical University Hospital, Riga, Latvia.
Int Arch Allergy Immunol
December 2024
Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, China.
Introduction: Atopy is an important and non-negligible clinical phenomenon in chronic spontaneous urticaria (CSU). However, the characteristics and clinical significance of atopy in patients with CSU have not been fully described. This study aimed to analyze the characteristics and clinical significance of atopy in patients with CSU.
View Article and Find Full Text PDFCureus
January 2024
Department of Medical Affairs and Clinical Research, Sun Pharma Laboratories Limited, Mumbai, IND.
Background: Chronic spontaneous urticaria (CSU) is a debilitating affliction that affects diverse quality of life (QoL) parameters such as sleep, self-esteem, and daily activities. Second-generation antihistamines, such as desloratadine, are more effective and safer in managing CSU. Desloratadine is a nonsedating, potent, and highly selective H1 receptor antagonist.
View Article and Find Full Text PDFAllergy Asthma Proc
November 2023
Division of Immunology and Allergic Diseases, Department of Internal Medicine, University of Health Sciences, Batman Training and Research Hospital, Batman, Turkey.
Although sleep disturbance is known to be common in patients with chronic spontaneous urticaria (CSU), sleep hormone levels in the blood have never before been studied in CSU. In this study, we aimed to evaluate the serum melatonin levels in patients with CSU. For the patient group, 80 patients with recently diagnosed CSU, and, for the control group, 75 healthy controls (HC) were included.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!